Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

UCB SA (UCBJF)

150.70
0.00
(0.00%)
At close: April 23 at 4:00:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for UCBJF

Recent News: UCBJF

View More
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
PR Newswire 21 days ago
UCB Convening Notice to the General Meeting of the Shareholders 2025

UCB Convening Notice to the General Meeting of the Shareholders 2025
GlobeNewswire last month
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference

New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
PR Newswire last month
Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome
PR Newswire last month
Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders

Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders
Benzinga last month
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
PR Newswire last month
BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
PR Newswire last month
UCB SA (UCBJF) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ...

UCB SA (UCBJF) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
GuruFocus.com last month
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
PR Newswire last month
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
PR Newswire 3 months ago
USNA or UCBJY: Which Is the Better Value Stock Right Now?

USNA or UCBJY: Which Is the Better Value Stock Right Now?
Zacks 3 months ago
View More

Related Tickers

KLDO Kaleido Biosciences, Inc.
0.0050
0.00%
 
EVLO Evelo Biosciences, Inc.
0.0005
0.00%
 
OPT Opthea Limited
3.4100
+1.49%
 
GLPG Galapagos NV
25.50
+1.67%
 
DYN Dyne Therapeutics, Inc.
10.78
+8.78%
 
MCRB Seres Therapeutics, Inc.
9.73
+19.24%
 
GPCR Structure Therapeutics Inc.
23.32
+1.22%
 
BNTX BioNTech SE
114.83
+9.70%
 
CRSP CRISPR Therapeutics AG
38.54
-1.76%
 
SMMT Summit Therapeutics Inc.
33.23
+21.50%